Hansoh Pharmaceutical's (HKG:3692) obtained clinical trial approval for its HS-10541 tablets from China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.
Shares of the pharma firm were down over 1% in Thursday afternoon trading.
The trial will study the drug for the treatment of patients with KRAS G12C-mutated advanced solid tumors.
Fujikura's (TYO:5803) profit attributable to owners of the parent surged 73% to 157.2 billion yen in fiscal year 2025 from 91.1 billion yen a year earlier.The telecommunications company's basic net profit per share increased to 94.93 yen from 55.05 yen a year ago, according to a Tokyo bourse filing on Thursday.Net sales climbed 21% to 1.182 trillion yen in the year ended March 31 from 979.4 billion yen in the prior year.Fujikura raised its final dividend to 130 yen per share from the initially planned 120 yen, payable from June 29.For fiscal year 2026, the company expects attributable profit of 156 billion yen, net profit per share of 94.22 yen, and net sales of 1.243 trillion yen.Fujikura plans to pay interim and year-end dividends of 19 yen per share each for the year, totalling 38 yen per share, which is lower than the 225 yen per share in the year-ago period on a pre-split basis.
Venky's (India) (NSE:VENKEYS, BOM:523261) said its net profit jumped to 1.01 billion Indian rupees in the fiscal fourth quarter from 133.0 million rupees a year ago, according to a Thursday filing on Indian bourses.Earnings per share for the quarter ended March 31 climbed to 71.96 rupees from 9.44 rupees a year earlier.Revenue from operations of the poultry company declined year on year to 11.0 billion rupees from 8.43 billion rupees.The board of Venky's recommended a dividend of 10 rupees per share for the fiscal year ended March 31.The company's shares plunged nearly 7% in recent trade.
CaoCao (HKG:2643) approved a share buyback plan of up to HK$200 million for a period of one year, according to a Thursday Hong Kong bourse filing.The ride-hailing company may buy back up to 54.4 million shares, representing 10% of its total shares in issue.The repurchased shares may be cancelled or held as treasury shares, depending on market conditions and capital management needs.